North America Arrhythmia Management System Market: Introduction
As per Reports and Insights Analysis, the North America Arrhythmia Management System (AMS) Market is expected to reach US$ 5,778.6 Mn by the end of year 2030. The market is projected to grow at a CAGR of 6.6%, and expected to create an incremental opportunity of US$ 2,324.1 Mn during the forecast period.
North America arrhythmia management system market is expected to grow by various factors such as rise in prevalence of cardiovascular diseases across the region and soaring technological advancements in cardiac monitoring devices and systems.
North America Arrhythmia Management System Market Analysis
The United States arrhythmia management system market size at the end of year 2022 is expected to reach at a value of US$ 2,516.6 Mn and market forecasted to grow at a CAGR of 6.9% during the period of 2022-2030. In 2021, the holter monitor technology segment is accounted to hold the largest market share followed by event monitors. On the basis of type segment, the type segment is divided into single channel and multi-channel. The single channel segment has led the North America market, in terms of revenue, in 2021.
On the basis of disease indication, the market is sub-divided into cardiovascular, angina pectoris, atherosclerosis, heart failure, and others. In terms of revenue, the cardiovascular disease indication holds the largest market share, owing to the rise in prevalence of cardiovascular diseases across the region.
Increased prominence of Mobile Cardiac Telemetry (MCT) is one of the major market opportunities for the North America Arrhythmia Management System (AMS) market
Mobile cardiac telemetry (MCT) can be perceived as a cardiac monitoring approach that utilizes a minor portable device to keep a watch on a patient’s cardiac movements. The MCT device registers the patient’s heartbeat as they sleep, run errands, exercise and carry on with their day. Mobile cardiac telemetry (MCT) is one of the most efficient means of cardiac monitoring. The potential to assess each heartbeat with tiny interferences to the patient’s usual day, and the possibility to begin a swift emergency response according to the needs, makes it one of the most appealing alternatives in the present day’s market. It offers benefits to both the patient and the medical practitioners that can pave its way to more effective care.
MCT is, in some measure, a novel technology, first sanctioned in 2002 by the US Food and Drug Administration (FDA), which offers uninterrupted real time outpatient electrocardiographic monitoring for extensive periods of time. MCT enables diagnosis of both symptomatic and asymptomatic arrhythmias and has been verified to offer excellent diagnostic potential for patients with palpitations, presyncope and syncope. The soaring trend of real-time patient monitoring and remote healthcare is majorly boosting the popularity of Mobile Cardiac Telemetry (MCT) monitors across the global markets. It is significant to note that Holter monitors are resolutely established as the standard device for remote cardiac monitoring.
However, a fresh survey indicates physicians are assured that mobile cardiac telemetry (MCT) can offer better discovery rates and more precise diagnosis. Attributing to such factors, the extensive demand of mobile cardiac telemetry monitors is estimated to offer major opportunities to the global arrhythmia management system market over the forthcoming years.
Integration of AI technology with cardiac monitoring devices and solutions is one of the major market trend explored in the study
Artificial Intelligence (AI) exhibited comprehensive capacities to influence various healthcare areas throughout the COVID-19 pandemic positively. The pandemic expedited the progress of artificial intelligence (AI) in the domain of remote patient care. Physicians and medics are more and more employing digital patient monitoring with a view to monitor health data in an improved manner, determine aberrations, and offer patient-specific treatment — everything without having an in-person interaction. These ground-breaking technologies are paving the way to greater results for patients and lessened healthcare costs. Over and above the advantages to patients, AI releases medical practitioners from administrative back-end work, such as reviewing through and managing huge datasets, and enables them to concentrate on practicing their clinical skills for patient care.
In January 2022, the leading merchant in the domain of remote patient monitoring and cardiac data management solutions, Implicity, obtained U.S. Food and Drug Administration (FDA) clearance for an innovative and unconventional medical algorithm that examines ECG data from implantable loop recorders (ILRs). The freshly 510(k) cleared ILR ECG Analyzer is an algorithm contingent on artificial intelligence (AI).
Key Players Analysis in North America Arrhythmia Management System Market
Some of the key participating players in North America arrhythmia management system market are Asahi Kasei Corporation, Koninklijke Philips N.V., ACS Diagnostics, BioTelemetry, Inc., Medicomp Inc., CardioView, Medtronic plc, Preventice Solutions, Inc., ScottCare Cardiovascular Solutions, Hill-Rom Holdings, Inc., and Schiller Americas, Inc.
North America Arrhythmia Management System Market Segmentation
The North America arrhythmia management system market is segmented by system type, modality, type, disease indication, end use industry and by region
Mobile Cardiac Telemetry (MCT) Devices
TELErhythmics Cardiac Ambulatory Telemetry (TCAT) Device
Insertable Cardiac Monitoring (ICM)
By Disease Indication
Ambulatory Surgical Centres
Reports and Insights
For Sales Query: [email protected]
For New Topics & Other Info: [email protected]